1 Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to

2 SARS-CoV-2

- 3 Douglas F. Lake^{1*#}, Alexa J. Roeder^{1*}, Erin Kaleta², Paniz Jasbi³, Sivakumar Periasamy^{4,5}
- 4 Natalia Kuzmina^{4,5} Alexander Bukreyev^{4,5,6}, Thomas Grys², Liang Wu⁷, John R Mills⁷, Kathrine
- 5 McAulay², Maria Gonzalez-Moa⁸, Alim Seit-Nebi⁸, and Sergei Svarovsky⁸
- 6

7 Affiliations:

- 8 1. School of Life Sciences, Arizona State University, Tempe AZ, USA
- Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ,
 USA
- 11 3. College of Health Solutions, Arizona State University, Phoenix AZ, USA
- Department of Pathology, University of Texas Medical Branch at Galveston, Galveston,
 TX USA
- Galveston National Laboratory, University of Texas Medical Branch at Galveston,
 Galveston, TX USA
- Department of Microbiology and Immunology University of Texas Medical Branch at
 Galveston, Galveston, TX USA
- Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester,
 MN USA
- 20 8. Axim Biotechnologies Inc, San Diego, CA USA
- 21 *Co-first authors
- 22
- 23 Running Head: Rapid Neutralization Test for COVID-19
- 24 #Address correspondence to Douglas F. Lake, douglas.lake@asu.edu
- 25
- 26 Douglas F Lake and Alexa J Roeder contributed equally to this work. Author order was
- 27 determined on the basis of seniority
- 28
- 29
- 30

31

32 Abstract:

33	As increasing numbers of people recover from and are vaccinated against COVID-19, tests are
34	needed to measure levels of protective, neutralizing antibodies longitudinally to help determine
35	duration of immunity. We developed a lateral flow assay (LFA) that measures levels of
36	neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that
37	neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to
38	angiotensin-converting enzyme 2 (ACE2). The LFA compares favorably with authentic SARS-
39	CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from
40	patients with seasonal coronaviruses did not prevent RBD from binding to ACE2. To
41	demonstrate the usefulness of the LFA for measuring antibodies in convalescent plasma used
42	for therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma.
43	This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively
44	inexpensive that might be useful in assessing COVID-19 vaccine-induced immunity.
45	

46

47 Introduction

The pandemic virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to be transmitted by person to person spread from its origin in Wuhan, China in December 2019(1–3). Vaccine trials are ongoing, and preliminary results from at least 2 vaccines show that the vaccines elicit protective immunity, but durability of vaccine responses is not known(4).

53 Molecular tests such as PCR detect SARS-CoV-2 nucleic acid in nasopharyngeal 54 secretions and saliva and are diagnostic of infection(5). These molecular tests can determine 55 the rate of infection and potential re-infection. When negative they indicate that patients have 56 cleared the virus. In response to infection, all immunocompetent hosts generate antibodies 57 against the virus. Patients may have a positive serologic test result as well as a PCR-positive

test result if they are early in convalescence(6). For SARS-CoV-2, antibodies to spike protein
do not always predict recovery from COVID-19(7).

60 Although immunocompetent individuals infected with SARS-CoV-2 generate antibodies 61 against the virus, it is essential to know which individuals generate high levels of neutralizing 62 antibodies (NAbs) so that they can resume normal activities without fear of being re-infected 63 and spreading the virus to others (8-10). The goal of COVID-19 vaccines is to induce NAbs and 64 T cell responses that prevent infection/re-infection. Additionally, development of NAbs indicates 65 which individuals might be optimal donors for convalescent plasma protocols. Although NAbs 66 are important for elimination of the virus and protection from subsequent infection, it has been 67 reported by several groups that up to one-third of convalescent plasma samples from individuals 68 who have recovered from COVID-19 do not neutralize SARS-CoV-2 or spike pseudotype virus 69 infection(11-13).

70 Viral neutralization assays measure levels of antibodies that block infection of host cells. 71 Two main types of viral neutralization assays are utilized for SARS-CoV-2. Authentic 72 microneutralization assays measure reduction of viral plaques or infectious foci in 73 microneutralization assays in susceptible host cells using SARS-CoV-2 under BSL3 conditions. 74 These assays are slow, laborious, require highly trained personnel and require a BSL3 facility. 75 Pseudotype virus neutralization assays have been developed in which SARS-CoV-2 spike 76 protein is expressed in a virus such as vesicular stomatitis virus or lentivirus(14, 15). These 77 assays are faster and less dangerous than authentic microneutralization assays, but still require 78 BSL2 conditions and 24-48 hours for results. Another challenge is that both authentic and 79 pseudovirus virus neutralization assays depend on host cells for infection which adds variability 80 to the assay.

81 It is known that SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to 82 bind angiotensin converting enzyme 2 (ACE2) on host cells; this appears to be the principal

83	neutralizing domain of SARS-CoV-2(16, 17). Using this knowledge, we developed a lateral flow
84	assay (LFA) that measures levels of (neutralizing) antibodies which block RBD from binding to
85	ACE2. Other groups have developed RBD-ACE2-based competition ELISAs(18)-(19) but none
86	have developed a rapid, highly portable semi-quantitative point-of-care (POC) test.
87	
88	Methods
89	Human Subjects and Samples
90	Peripheral blood, serum and plasma were collected for this study under an Arizona State
91	University institutional review board (IRB) approved protocol #0601000548 and Mayo Clinic IRB
92	protocol #20-004544. Plasma was obtained by ficoll gradient separation of peripheral blood and
93	serum was obtained by centrifugation 30 minutes after drawing blood. Plasma and serum
94	samples obtained from excess clinical samples at Mayo Clinic were pre-existing, de-identified
95	and leftover from normal workflow. COVID-19 samples ranged from 3 to 84 days post PCR
96	positive result. Residual clinical samples were stored at 2-8°C for up to 7 days, and frozen at
97	-80°C thereafter.
98	Serum samples from patients with non-COVID-19 respiratory illnesses were also tested.
99	These specimens were collected from patients from 2/14/17 – 4/6/20 and were tested by the
100	FilmArray Respiratory Panel 2 (RP2) (Biofire Diagnostics, Salt Lake City, UT) respiratory virus
101	panel as part of routine clinical workflow. Specimens were stored at -80°C until analysis.
102	
103	Pseudotype Virus Neutralization Assays
104	Titers were obtained from 60 COVID-19 patient sera using a vesicular stomatitis virus (VSV)
105	spike protein pseudotype assay as previously reported with modifications (14). Patient sera had
106	been stored at -80°C prior to testing. Briefly, SARS-CoV-2 pseudotypes were created by
107	replacing VSV G glycoprotein with SARS-CoV-2 spike protein resulting in a pseudotyped virus
108	with the C-terminal 19 amino acids removed from spike. The pseudotyped virus is called VSV-

109 SARS-CoV-2-S-∆19CT and was produced by BHK-21 cells. It induces syncytium formation 110 when incubated with vero cells. Two different Vero cells encoding split product luciferase 111 (DSP1 and DSP2) were cultured at a 1:1 ratio as a monolayer. Virus-induced fusion leads 112 to luciferase complementation and in the presence of luciferase substrate 113 EnduRenTM (Promega, Madison, WI) generates luminescence. The higher luminescence, the 114 more infection events by the virus. A human monoclonal antibody (Regeneron, Tarrytown, 115 NY) targeting the SARS-CoV-2 spike protein was diluted to set a cut-off at 50% neutralizing 116 activity and utilized as a single point calibrator. Patient sera with serial dilutions (1:80-117 1:2560) and the calibrator were pre-incubated with virus for 30 minutes (neutralization) prior to 118 addition to DSP1 and DSP2 Vero cells. The virus-cell mixture was incubated at 37°C in a 5% 119 C0₂ incubator for a total of 24 hours before luminescence reading; the substrate 120 EnduRenTM was added at 18 hours of incubation. The raw luminescence signal of each sera 121 dilution was compared against the raw luminescence signal of the calibrator. The 122 last consecutive dilution with luminescence signal below the calibrator was considered the end-123 point titer. Samples were tested in duplicate. The same serum samples, 68 coded sera (10 124 serum samples at titers of 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560 and 8 serum samples from 125 individuals never infected with COVID-19) were frozen at -20°C and shipped by Dr. Mills from 126 Mayo Clinic Rochester to Mayo Clinic Arizona and the Lake Lab for LFA testing.

127

128 Authentic SARS-CoV-2 Microneutralization Assay

The authentic microneutralizing assay was performed using a recombinant SARS-CoV-2 that expresses mNeonGreen (SARS-CoV-2ng) during replication in permissive cells, as previously described (20). Inhibitory concentrations for which 50% of virus is neutralized by serum antibodies (IC₅₀ values) were obtained on a unique set of 38 COVID-19 sera. Sixty μ I aliquots of SARS-CoV-2ng were pre-incubated for 1 h in 5% CO₂ at 37°C with 60 μ I serial 2-fold serum

134 dilutions in cell culture media, and 100µl were inoculated into Vero-E6 monolayers in black 135 polystyrene 96-well plates with clear bottoms (Corning, Tewksbury, MA). Each serum was 136 tested in duplicates. The final amount of the virus was 200 PFU/well, and the starting serum 137 dilution was 1:20 and the end dilution was 1280 unless an IC_{50} was not reached in which case 138 serum was diluted to 1:10240. Cells were maintained in Minimal Essential Medium 139 (ThermoFisher Scientific, Waltham, MA) supplemented by 2% FBS (HyClone, Logan, UT) and 140 0.1% gentamycin in 5% CO₂ at 37°C. After 2 days of incubation, fluorescence intensity of 141 infected cells was measured at a 488 nm wavelength using a Synergy 2 Cell Imaging Reader 142 (Biotek, Winooski, VT). The signal readout was normalized to virus control aliguots with no 143 serum added and was presented as the percentage of neutralization. IC_{50} was calculated with 144 GraphPadPrism 6.0 software. Work with infectious SARS-CoV-2ng was performed in a BSL-3 145 biocontainment laboratory of the University of Texas Medical Branch, Galveston, Tx, Galveston 146 National Laboratory.

147

148 Serologic Antibody Assay

149 The Ortho Vitros Anti-SARS-CoV-2 IgG test was performed on the Ortho Clinical 150 Diagnostics Vitros 3600 Immunodiagnostics System (Ortho, Raritan, NJ) following 151 manufacturer's instructions at the Mayo Clinic. This assay is approved for use in clinical testing 152 under FDA Emergency Use Authorization to gualitatively detect antibody to the S1 subunit of 153 SARS-CoV-2 spike protein. Results are reported as reactive (S/CO \ge 1.0) or Nonreactive (S/CO 154 <1.0). Quantitative results are not reported for clinical workflows but are measured and recorded 155 in this assay. Specimens were tested within 7 days of collection and were stored at 2-8°C per 156 manufacturer's instructions. This assay was performed after the VSV assay was performed on 157 the set of 60 serum samples, then the samples were frozen at -80°C before running them on the 158 LFA. A separate set of 38 samples was run concurrently in the SARS-CoV-2 authentic 159 microneutralizing antibody assay, the LFA, and the Ortho Vitros Anti-SARS-CoV-2 IgG assay.

160 Lateral Flow Neutralizing Antibody Assay

161 The Lateral Flow Neutralizing Antibody assay was developed to detect antibodies that 162 compete with ACE2 for binding to RBD. The LFA cassette contains a test strip composed of a 163 sample pad and blood filter, conjugate pad, nitrocellulose membrane striped with test and 164 control lines, and an absorbent pad to wick excess moisture (Axim Biotechnologies Inc, San 165 Diego, CA). The blood filter allows serum to pass through but prevents red blood cells and 166 leukocytes from interfering with the assay. Test strips are secured in a cassette that contains a 167 single sample port (Empowered Diagnostics, Pompano Beach, FL). For procedural control 168 purposes, the LFA also contains a control mouse antibody conjugated to red gold nanospheres 169 and corresponding anti-mouse control line.

LFAs were performed at ambient temperature and humidity on a dry, flat surface and left to run undisturbed for 10 minutes prior to reading results. First, 10µl of plasma, serum or whole blood were transferred to the cassette sample port and immediately followed by two drops (~50µl) of chase buffer. After 10 minutes, each test was placed in an iDetekt RDS-2500 LFA reader (Austin, TX) and the densities of both test and control lines were recorded electronically. This assay was performed on the VSV subset (n = 60) as well as the authentic SARS-CoV-2 microneutralizing antibody assay subset (n = 38).

Serum samples from COVID-19 patients as well as sera from patients with PCRconfirmed seasonal respiratory viruses including PCR-confirmed seasonal coronaviruses were
tested in the LFA as controls. Twenty-seven sera from patients with seasonal respiratory
viruses were tested in the LFA in a manner identical to COVID-19 sera.

The test leverages the interaction between RBD-conjugated green-gold nanoshells
 (Nanocomposix, San Diego, CA) that bind ACE2 at the test line when RBD-binding/neutralizing

antibodies (RBD-NAbs) are absent or low. As indicated by the competitive nature of this assay,
test line density is inversely proportional to RBD-NAbs present within the sample. Thus, an
absent or faint test line indicates high levels of RBD-NAbs, whereas a dark or strong test line
suggests lack of RBD-NAbs within a given plasma sample (Figure 1A).

As a semi-quantitative test, the results of the LFA can be interpreted using a scorecard or a densitometer. Figure 1B demonstrates the scorecard. Red control line across from the "C" on the cassette is composed of a mouse monoclonal antibody coupled to red-gold beads binding to an anti-mouse IgG. A red line indicates that the test ran properly and the green test line across from the "T" can be used to semi-quantitatively measure the ability of plasma, serum or whole blood to block RBD on green-gold nanoshells from binding to ACE2.

To demonstrate the ability of the test to measure NAbs in whole blood, 10µg of a
neutralizing monoclonal antibody (mAb) based on the sequence of B-38(20)(Axim
Biotechnologies, Inc, San Diego, CA) was mixed with 10µl of normal donor whole blood
collected in a heparinized blood collection tube. Two-fold dilutions were made in whole blood to
a final concentration of 0.625µg/ml neutralizing mAb. Then, 10µl of each dilution were
transferred to LFA cassettes, chased with 50µl running buffer, and read with an LFA reader after
10 minutes.

200

201 Conversion of Non-immune Normal Human Plasma (NIHP) into Neutralizing Plasma

To convert NIHP into strongly neutralizing plasma (SNP), plasma from a convalescent donor who demonstrated the ability to block RBD from binding to ACE2 (M21) was mixed with NIHP collected prior to December 2019. For example, for a 1% mixture, 1µl of SNP was mixed with 99µl NIHP; for a 5% mixture 5µl of SNP was admixed with 95µl NIHP, etc. We performed the test with 10µl of 1%, 5%, 10%, and 20% SNP admixed into NIHP.

208 Data Analysis

209 Pearson's correlation (r) was conducted to assess the strength and significance of 210 associations between the LFA, the Ortho Vitros Anti-SARS-CoV-2 IgG test, VSV titers and IC₅₀ 211 values. Regression analysis using IC_{50} values was performed to evaluate consistency(18) while 212 Bland-Altman plots were constructed to assess agreement and bias(21, 22). Correlation analysis 213 was conducted using IBM SPSS (Armonk, NY). Regression analysis was performed using 214 Microsoft Excel (Redmond, WA); Bland-Altman plots were visualized using IBM SPSS. For two-215 group analysis, IC_{50} values corresponding to >240 were categorized as titer of >1:320 216 (neutralizing), whereas IC₅₀ values \leq 240 were categorized as \leq 1:160 (non-neutralizing). Receiver 217 operating characteristic (ROC) analysis was performed to assess classification accuracy, 218 sensitivity, and specificity of the LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test methods in 219 assessing neutralizing capacity; optimal cutoffs for each method were established to maximize 220 area under curve (AUC)(23, 24). ROC analysis was conducted using R language in the RStudio 221 environment (version 3.6.2; RStudio PBC, Boston, MA). All analyses were conducted using raw 222 values; data were not normalized, transformed, or scaled.

223

224 Results

225 The lateral flow assay reported here is a rapid 10-minute POC test. As shown in the 226 schematic in Figure 1A, this test utilizes serum, plasma or whole blood to semi-quantitatively 227 measure levels of NAbs. An example of strong, moderate and non-neutralizing sera is shown in 228 Figure 1B. As diagrammed in Figure 1A, levels of NAbs in serum or plasma are reflected by 229 the intensity of the test line which can be read on a hand-held densitometer or compared 230 visually to a scorecard (Figure 1B). Strong neutralization results in a weak line because 231 neutralizing antibodies are binding RBD on green gold beads and preventing RBD-beads from 232 binding to the ACE2 cellular receptor at the test line.





248 **Figure 1.**

249 (A) Schematic of Neutralization LFA. Below each graphic is a representative image of a lateral 250 flow strip demonstrating actual line density. Addition of non-COVID19-immune serum or plasma 251 (top) does not block binding of RBD-beads (green particles) to ACE2 resulting in the RBD-252 bead-ACE2 complex creating a visible line. Addition of patient serum with moderate titer NAbs 253 to the sample pad creates a weak line (*middle*). Addition of patient serum with high titer NAbs 254 (> 1:640) blocks binding of RBD-beads to ACE2 such that no line is observed at the test 255 location on the strip (bottom). Red control line represents capture of a mouse monoclonal 256 antibody coupled to red beads. (B) Scorecard for measuring levels of NAbs . Red control line across from the "C" on the cassette indicates that the test ran properly and the green test line 257 258 across from the "T" can be used to measure the ability of plasma or serum to block RBD on gold 259 nanoshells from binding to ACE2. (0) represents patient serum producing a visually non-existent 260 line with density units of 10,095 and an IC_{50} >500 (IC_{50} =1151); (1) represents patient serum with a line density of 132,503 and an IC₅₀ of 396; (2) represents patient serum with a line density of 261 262 239,987 and an IC_{50} of 243; (3) represents patient serum with a line density of 485,665 and an 263 IC₅₀ of 96.

264

265 We tested 60 serum samples with known neutralization titers obtained in a VSV-based

spike pseudotype assay in our LFA. De-identified serum samples were sent from Mayo Clinic

- 267 Rochester to our laboratories at Mayo Clinic Arizona and run in a blinded manner. The LFA
- 268 result compared favorably with serum titers, especially at higher titers and correctly
- 269 distinguished all eight non-neutralizing serum samples (**Figure 2A**).

To further support the application of our lateral flow test to measure levels of antibodies that neutralize SARS-CoV-2, we tested a different set of 38 serum samples that were assigned IC_{50} values in an authentic SARS-CoV-2 microneutralization assay(25). Again, the experiment was performed in a blinded manner such that personnel running either the LFA or the microneutralization assay did not know the results of the comparator test. When line densities from the LFA were plotted against IC_{50} values determined in the SARS-CoV-2 microneutralization

assay, serum samples with strong neutralization activity demonstrated low line densities; this indicates that neutralizing antibodies inhibited RBD from binding to ACE2 (**Figure 2B**).

278





Figure 2. (A) Comparison of RBD-ACE2 competition LFA Density Units with VSV-Spike

pseudotype virus assay titers using 60 convalescent serum samples. Titers from the
 pseudotype assay are shown on the X-axis. Scatter plots with bar graph including standard

deviation of the mean for 10 serum samples at each titer except for negative donor serum which

is eight samples. (B) Comparison of RBD-ACE2 competition LFA with IC₅₀ values determined in

a SARS-CoV-2 microneutralization assay on 38 samples (collected 3 to 90 days after PCR

positive result). Ranges of IC₅₀ values are shown on the X-axis plotted against LFA line density

- 287 units on the Y-axis.
- 288

Next, we determined if our test detected any neutralization activity in serum samples
 collected from patients with other PCR -confirmed respiratory viruses including seasonal
 coronaviruses (Figure 3A) and for serum samples collected prior to December 2019 (Figure
 3B). None of the seasonal respiratory virus plasma samples, including pre-December 2019
 samples showed neutralizing activity.















302 A positive control serum from a convalescent COVID-19 patient is shown on the far right of the 303 bar graph in white. B) Serum samples collected pre-December 2019. Cutoff value of 263,000 304 density units was calculated based on receiver operating characteristic curves (see Figure 6). 305 306 We evaluated how the Ortho Vitros Anti-SARS-CoV-2 IgG test and our LFA compared to 307 IC₅₀ values determined in an authentic SARS-CoV-2 microneutralization assay using 38 COVID-308 19 sera. FDA guidance indicates that an Ortho Vitros Anti-SARS-CoV-2 IgG test of ≥12 meets a 309 threshold for convalescent plasma use in patients with COVID-19. To determine the agreement 310 between our lateral flow assay and the Ortho Vitros Anti-SARS-CoV-2 IgG test, density units from 311 our LFA and values from the Ortho test were regressed onto IC_{50} values (**Figure 4**).

312



Figure 4. Regression analysis between (A) LFA and serum titer, and (B) Ortho Vitros SARS-CoV-2 IgG test and titer. Regression plots show explained variance (R^2) between compared methods. Thirty-eight samples were tested.

LFA values accounted for roughly 52% of observed variance in IC₅₀ values, while Ortho Vitros Anti-SARS-CoV-2 IgG test accounted for approximately 27% of IC₅₀ variance. Since the format of the LFA reports decreasing density values as neutralization increases, LFA was significantly inversely correlated with IC₅₀ values (r = -0.720, p < 0.001), while Ortho Vitros Anti-SARS-CoV-2 IgG test values showed a significant positive correlation to IC₅₀ values (r = 0.522, p= 0.001). Additionally, LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test values showed a significant relationship with each other (r = -0.572, p < 0.001).

To evaluate bias between the assays, mean differences and 95% confidence intervals (CIs) were calculated and plotted alongside limits of agreement (**Figure 5**). Both LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test values showed high agreement with titer, although Ortho Vitros Anti-SARS-CoV-2 IgG test showed a tendency to underestimate neutralizing capacity while the LFA method showed no bias.

330





Figure 5. Bland-Altman plots showing bias (mean difference and 95% CI) and computed limits
 of agreement (mean difference ± 2SD) between (A) Ortho Vitros Anti-SARS-CoV-2 IgG test and
 IC₅₀ values and (B) our LFA and IC₅₀ values. Thirty-eight samples were tested.

336 Univariate ROC analysis was performed to assess the performance of the newly 337 developed LFA and Ortho assay to classify non-neutralizing (Neg-1:160), and neutralizing 338 groups (≥1:320) (Figure 6). As can be seen in Figure 6B and 6D, the LFA misclassified one non-339 neutralizing sample (Neg—1:160) as neutralizing (≥1:320). In contrast, Ortho Vitros Anti-SARS-340 CoV-2 IgG test misclassified that same non-neutralizing sample as neutralizing, in addition to 341 incorrectly classifying five additional neutralizing samples as non-neutralizing. Importantly, our 342 LFA method exhibited a greater dynamic range of differential values as compared to Ortho's test. 343 (Figure 5), translating to superior classification accuracy of the LFA method in detecting 344 neutralizing samples (titer ≥ 1:320) compared to Ortho Vitros Anti-SARS-CoV-2 IgG test (Figures 345 6A and 6C).



347

Figure 6. (A) Univariate ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test for discrimination of neutralizing samples (\geq 1:320) [AUC: 0.856, 95% CI: 0.697—0.953, sensitivity = 0.7, specificity = 0.9]. **(B)** Box plot of Ortho Vitros Anti-SARS-CoV-2 IgG test values between neutralizing (\geq 1:320) and non-neutralizing (Neg—1:160) groups. **(C)** Univariate ROC analysis of LFA for discrimination of neutralizing samples (\geq 1:320) [AUC: 0.978, 95% CI: 0.908—1.0, sensitivity = 1.0, specificity = 0.9]. **(D)** Box plot of LFA values between neutralizing (\geq 1:320) and non-neutralizing (Neg—1:160) groups.

355

Our LFA showed high accuracy for classification of neutralizing samples (AUC = 0.978), while the Ortho Vitros Anti-SARS-CoV-2 IgG test showed modest accuracy for classification of neutralizing samples (AUC = 0.856). Furthermore, while the LFA method showed a narrow confidence interval (95% CI: 0.908—1.00), ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test values showed a wider range (95% CI: 0.697—0.953), indicating less certainty. Notably, while both methods showed roughly 90% specificity, Ortho Vitros Anti-SARS-CoV-2 IgG test Vitros Anti-

363 SARS-CoV-2 IgG test showed only 70% sensitivity. In contrast, the novel LFA method showed
 364 perfect sensitivity (100%) in this analysis of 38 samples.

Optimal cutoffs were computed to maximize AUC. For the LFA, density unit values below 263,000 classify samples as neutralizing and correspond to titers \geq 1:320. Density unit values above this LFA cutoff classify samples in the non-neutralizing group. For the Ortho Vitros Anti-SARS-CoV-2 IgG test, values between 0 and 23.3 were representative of non-neutralizing capacity, whereas values above 23.3 were reflective of the neutralizing group. If we used the FDA cutoff of 12 instead of the 23.3 value calculated using our results, AUC would be reduced to 0.69 (sensitivity = 0.55, specificity = 0.83).

372 Polyclonal antisera was used in this study, not an individual Mab, so the limit of detection 373 (LoD) does not exactly apply). However, we can calculate the LoD by line density based on the 374 method of Armbruster and Pry(26) as the highest line density from samples still containing 375 neutralizing antibodies and distinguishable from blank except that the operand sign was changed 376 because due to the competitive format of the LFA: LoD= limit of blank (LoB) - (1.65* SD_{low conc} 377 sample): LoD=1,047,382- (1.65 * 63,769)= 942,481 Test Line Density Units. The average line 378 density observed for the top 10 donors who demonstrated the strongest ability to prevent RBD 379 from binding to ACE2 was 20,706.

380 The principle of infusing convalescent plasma from recovered individuals into patients 381 fighting COVID-19 is to transfer NAbs from the donor to the recipient, as has been done for 382 several other diseases(27–29). The rapid test described here, could quickly and efficiently 383 classify COVID-19 convalescent plasma (CCP) units so that the sickest patients might receive 384 the most potently neutralizing plasma. Although levels of neutralizing antibody to achieve in 385 patients receiving CCP remains undefined, our point-of-care test might be useful at the bedside 386 to monitor a patient receiving highly neutralizing CCP as he/she begins to demonstrate NAbs in 387 circulation, as shown in **Figure 7A**. It could help in deciding whether to administer another unit

- 388 of highly neutralizing CCP to a patient fighting COVID19. The same scenario might also be
- 389 applied to hyperimmune gammaglobulin or neutralizing monoclonal antibody infusion.

390 To demonstrate the utility of our LFA to measure NAbs in whole blood, we used a lateral

- 391 flow strip with a blood filter and performed an experiment in which a neutralizing monoclonal
- antibody based on the B-38(20) sequence was titrated into whole blood as shown in **Figure 7B**.
- 393 Density units were not obtained in these experiments but both Figures 7A and 7B demonstrate
- 394 the semi-quantitative nature of this test to visually distinguish different levels of NAbs in plasma
- and whole blood.



Figure 7. (A) Highly neutralizing plasma from an individual recovered from COVID-19 (M21)
converts non-immune human plasma (ND82) into highly neutralizing plasma; 10µl of plasma
was added to each lateral flow cassette. Text below each lateral flow cassette indicates the
percent M21 and percent ND82 plasma used to run the lateral flow test. (B) Titration of antiRBD neutralizing mAb into 10µl of heparinized whole blood. For both types of cassettes,
plasma or blood sample was immediately chased with 50µl sample buffer. Densities were read
and cassettes were imaged after 10 minutes development.

437438 Discussion

439 Serologic tests that detect responses to infection are an important population

440 surveillance tool during pandemics because they provide data on pathogen exposure, especially

441 when a subset of the population is asymptomatic and would not have been diagnosed by molecular methods(30, 31). While over 90% of individuals diagnosed with COVID-19 generate 442 443 antibody responses(30) we are only beginning to learn about the prevalence and duration of 444 NAbs induced by a natural infection. This lack of knowledge is mainly due to the fact that virus-445 based neutralization assays require i) BSL2 or BSL3 facilities, ii) highly skilled personnel, iii) 446 permissive cells and quantified virus, and iv) take longer than 24 hours to obtain results. Since 447 every viral vaccine, including COVID-19 vaccines, administered to humans is designed to elicit 448 antibodies that neutralize virus by blocking host cell infection, development of NAbs is a 449 hallmark of protection from disease. Therefore, there is a need for rapid, accurate tests that 450 measure levels of NAbs. Furthermore, in a post-vaccine world, longitudinal measurement of 451 protective, neutralizing antibodies is crucial. Measurement of anti-viral T cells also indicates that 452 infected individuals could destroy infected host cells if virus escapes neutralization.

We developed a rapid, 10-minute lateral flow test that measures levels of NAbs in serum and plasma. As shown in **Figure 2**, the lateral flow test correlates well with serologic titers determined using a VSV-based pseudotype assay, and IC_{50} values in an authentic SARS-CoV-2 microneutralization assay, especially when serum sample titers are \geq 640 and IC_{50} values are \geq 250. Samples with less potent NAbs in both viral assays correlated with decreased ability to block RBD from binding to ACE2 in the LFAs.

459 The LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test methods showed a strong, 460 significant correlation with each other (r = -0.572, p < 0.001), displaying an appreciable degree of linear relation (r = -0.720, p < 0.001)(32). Importantly, LFA accounts for 52% of observed IC₅₀ 461 462 variance ($R^2 = 0.5187$) while, in comparison, Ortho Vitros Anti-SARS-CoV-2 IgG test accounts for 463 27% ($R^2 = 0.2725$). Although absolute quantitation of a construct demands an excellent coefficient of determination ($R^2 \ge 0.99$)(33), variables with $R^2 \ge 0.5$ are highly predictive in univariate 464 regression models while measures with $R^2 < 0.5$ are recommended for use in multivariate models 465 in combination with complementary measures to increase predictive accuracy(34, 35). 466

Additionally, Bland-Altman analysis (**Figure 5**) showed the Ortho Vitros Anti-SARS-CoV-2 IgG test to be prone to underestimation of IC_{50} values. In contrast, the LFA method did not exhibit any over- or underestimation bias. Furthermore, across mean values for both methods, LFA showed discrete differential values while Ortho Vitros Anti-SARS-CoV-2 IgG test struggled to differentiate samples with high neutralizing capacity (IC₅₀ values).

472

473 Since the Ortho Vitros Anti-SARS-CoV-2 IgG test uses S1, which includes RBD, it is 474 likely that antibodies reactive with other parts of S1-even some that may neutralize via N-475 terminal domain-are responsible for increased reactivity to S1 when they are not neutralizing in 476 our RBD-ACE2 competition assay. Advantages of our POC test is that it can be inexpensively 477 and rapidly deployed in studies to determine levels of NAbs that protect against re-infection and 478 limit transmission of the virus. Moreover, rapid inexpensive tests can be used longitudinally to 479 evaluate duration of protective immunity in both naturally infected and many more vaccinated 480 individuals than could ever be evaluated using BSL2 or BSL3-based neutralization assays.

481

482 In the setting of much debated CCP, a rapid test could be used to measure levels of 483 NAbs in a CCP product prior to infusion, or potential donors who recovered from COVID-19. 484 During infusion of CCP, a rapid test could be used to help decide if a patient fighting COVID-19 485 requires another unit of highly neutralizing plasma. If a particular donor's CCP has very high 486 levels of CCP, patients might need only one unit. On the other hand, if donor CCP contains 487 moderate levels of NAbs, the patient may require multiple units to achieve therapeutic levels of 488 NAbs. However, since we do not know what an adequate therapeutic dose of NAbs is, this 489 rapid test could be a valuable tool in trials to determine under what conditions CCP. 490 hyperimmune globulin, and neutralizing mAbs are effective therapeutic agents for COVID19 491 patients.

Limitations of the LFA are that it uses only the RBD portion of SARS-CoV-2 spike protein. Although the vast majority of reports indicate that the principle neutralizing domain is RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by binding to the N-terminal domain of spike protein(36, 37). Also, since the spike protein assumes several conformations during viral binding and entry(38), neutralizing epitopes exist on the quaternary structure of spike(37). Although RBDs on the nanoparticles may associate, it is unlikely they assume a native guaternary conformation.

500 Other limitations are the binary nature of the data analysis (neutralizing and non-501 neutralizing) of a continuous assay. Clearly, line densities demonstrate moderate levels of 502 neutralization. Since blood draws and subsequent assays are a "snapshot in time" of 503 neutralizing antibody activity, levels were undoubtedly increasing in some patients and 504 decreasing in others. LFAs are generally inexpensive and highly portable compared to other 505 laboratory-based tests, so neutralizing antibody levels could be measured using the LFA to 506 longitudinally assess protective neutralizing antibody immunity. Another limitation is that the 507 LFA does not differentiate high affinity anti-RBD NAbs from an abundance of lower affinity anti-508 RBD NAbs. In related experiments, we have observed patient sera that bind strongly to RBD, 509 but do not demonstrate neutralizing activity (data not shown).

510 This test may prove very useful in monitoring COVID-19 vaccine recipients. Although 511 vaccines have now been approved for distribution and administration, durability of protective 512 immunity elicited by any COVID-19 vaccine is unknown. It is the goal of all COVID-19 vaccines 513 to induce protective NAbs. However, since clinical trials of vaccines have enrolled 30,000 to 514 60,000 participants, it is not logistically possible to draw a tube of blood from each vaccine 515 recipient longitudinally to determine duration of protective NAbs. Application of our test in 516 vaccine recipients using a drop of blood obtained from a finger-stick as shown in Figure 7B 517 might lead to more comprehensive longitudinal monitoring of increases and decreases in 518 protective humoral immunity.

519

520 Data availability

521 The authors declare that data supporting the findings of this study are available within the

- 522 paper. Additional data mentioned but not shown are available from the corresponding author
- 523 upon reasonable request.
- 524

525 **References**

- 526 1. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, Rubin R, Morales-Estrada S,
- 527 Black SR, Pacilli M, Fricchione MJ, Chugh RK, Walblay KA, Ahmed NS, Stoecker WC, Hasan NF,
- 528 Burdsall DP, Reese HE, Wallace M, Wang C, Moeller D, Korpics J, Novosad SA, Benowitz I, Jacobs
- 529 MW, Dasari VS, Patel MT, Kauerauf J, Charles EM, Ezike NO, Chu V, Midgley CM, Rolfes MA, Gerber
- 530 SI, Lu X, Lindstrom S, Verani JR, Layden JE, Brister S, Goldesberry K, Hoferka S, Jovanov D, Nims D,
- 531 Saathoff-Huber L, Hoskin Snelling C, Adil H, Ali R, Andreychak E, Bemis K, Frias M, Quartey-
- 532 Kumapley P, Baskerville K, Murphy E, Murskyj E, Noffsinger Z, Vercillo J, Elliott A, Onwuta US, Burck
- 533 D, Abedi G, Burke RM, Fagan R, Farrar J, Fry AM, Hall AJ, Haynes A, Hoff C, Kamili S, Killerby ME,
- 534 Kim L, Kujawski SA, Kuhar DT, Lynch B, Malapati L, Marlow M, Murray JR, Rha B, Sakthivel SKK,
- 535 Smith-Jeffcoat SE, Soda E, Wang L, Whitaker BL, Uyeki TM. 2020. First known person-to-person
- 536 transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The
- 537 Lancet 395:1137–1144.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu
 W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao
 B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The
 Lancet 395:497–506.

542	3.	Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial undocumented infection
543		facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 368:489–493.
544	4.	Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison
545		MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD,
546		Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara V-V, Floyd K, Suthar MS,
547		Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2020. Durability of
548		Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med 4.
549	5.	Loeffelholz MJ, Tang Y-W. 2020. Laboratory diagnosis of emerging human coronavirus infections –
550		the state of the art. Emerg Microbes Infect 9:747–756.
551	6.	Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal patterns of
552		nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg
553		Microbes Infect 9:833–836.
554	7.	McAndrews KM, Dowlatshahi DP, Hensel J, Ostrosky-Zeichner LL, Papanna R, LeBleu VS, Kalluri R.
555		2020. Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding
556		domain does not predict rapid recovery from COVID-19. preprint, Infectious Diseases (except
557		HIV/AIDS).
558	8.	Han Z, Battaglia F, Terlecky SR. 2020. Discharged COVID-19 Patients Testing Positive Again for SARS-
559		CoV-2 RNA: A Minireview of Published Studies from China. J Med Virol jmv.26250.
560	9.	Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, Li Y, Wang X. 2020. Clinical characteristics of severe acute

561 respiratory syndrome coronavirus 2 reactivation. J Infect 80:e14–e17.

- 562 10. Hoang VT, Dao TL, Gautret P. 2020. Recurrence of positive SARS-CoV-2 in patients recovered from
 563 COVID-19. J Med Virol jmv.26056.
- 11. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan
- 565 A, Finkin S, Hagglof T, Oliveira TY, Viant C, Hurley A, Hoffmann H-H, Millard KG, Kost RG, Cipolla M,
- 566 Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H,
- 567 Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak
- 568 JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Rice CM, Hatziioannou T, Bjorkman PJ,
- 569 Bieniasz PD, Caskey M, Nussenzweig MC. 2020. Convergent Antibody Responses to SARS-CoV-2
- 570 Infection in Convalescent Individuals. preprint, Immunology.
- 571 12. Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant
- 572 FL, Gherardin NA, Pymm P, Dietrich MH, Scott NE, Tham W-H, Godfrey DI, Subbarao K, Davenport
- 573 MP, Kent SJ, Wheatley AK. 2020. Immunogenic profile of SARS-CoV-2 spike in individuals recovered
- 574 from COVID-19. preprint, Infectious Diseases (except HIV/AIDS).
- 575 13. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang
- 576 J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort
- 577 and their implications. MedRxiv Prepr 20.
- 578 14. Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, Buehler J, Suksanpaisan L, Naik S,
- 579 Brunton B, Recker J, Haselton M, Ziegler C, Roesler A, Mills JR, Theel E, Weaver SC, Rafael G,
- 580 Roforth MM, Jerde C, Tran S, Diaz RM, Bexon A, Baum A, Kyratsous CA, Peng KW, Russell SJ. 2020.
- 581 Development and validation of IMMUNO-COV[™]: a high-throughput clinical assay for detecting
- 582 antibodies that neutralize SARS-CoV-2. preprint, Immunology.

583	15. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D,
584	Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and reagents for pseudotyping
585	lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. preprint, Microbiology.
586	16. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y, Wang Q, Zhou H, Yan J,
587	Qi J. 2020. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell
588	S009286742030338X.

- 589 17. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L,
- 590 Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse
- 591 LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. 2020. The receptor
- 592 binding domain of the viral spike protein is an immunodominant and highly specific target of
- 593 antibodies in SARS-CoV-2 patients. Sci Immunol 5:eabc8413.
- 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chen VC-W, Young BE, Sia WR, Tan Y-J, Foo R,
- 595 Yi Y, Lye DC, Anderson DE, Wang L-F. 2020. A SARS-CoV-2 surrogate virus neutralization test based
- 596 on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol
- 597 https://doi.org/10.1038/s41587-020-0631-z.
- 598 19. Hanson QM, Wilson KM, Shen M, Itkin Z, Eastman RT, Shinn P, Hall MD. 2020. Targeting ACE2-RBD
- interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of
 an AlphaLISA proximity assay. preprint, Biochemistry.
- 601 20. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, Xiao H, Fan Z, Tan S, Wu
- 602 G, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao GF, Gao F, Liu L. 2020. A noncompeting
- pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science
 368:1274–1278.

- 605 21. Davide Giavarina. 2015. Understanding Bland Altman analysis. Biochem Medica 25:141–151.
- 606 22. Doğan NÖ. 2018. Bland-Altman analysis: A paradigm to understand correlation and agreement. Turk
- 607 J Emerg Med 18:139–141.
- 608 23. Obuchowski NA, Bullen JA. 2018. Receiver operating characteristic (ROC) curves: review of methods
 609 with applications in diagnostic medicine. Phys Med Biol 29.
- 610 24. Nakas CT, Yannoutsos CT. November 30. Ordered multiple-class ROC analysis with continuous
- 611 measurements. Med Stat 23:3437–49.
- 612 25. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE,
- 613 Aguilar PV, Plante KS, Weaver SC, Makino S, LeDuc JW, Menachery VD, Shi P-Y. 2020. An Infectious
- 614 cDNA Clone of SARS-CoV-2. Cell Host Microbe 27:841-848.e3.
- 615 26. Armbruster DA, Pry T. Limit of Blank, Limit of Detection and Limit of Quantitation. 2008 Clin
 616 Biochem Rev 29:s50.
- 617 27. Leider JP, Brunker PAR, Ness PM. 2010. Convalescent transfusion for pandemic influenza: preparing
- 618 blood banks for a new plasma product?: CONVALESCENT TRANSFUSION FOR PANDEMIC
- 619 INFLUENZA. Transfusion (Paris) 50:1384–1398.
- 620 28. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, Wan H-L, Chen J-H, Hu B-S, Perng C-L, Lu J-
- 521 J, Chang F-Y. 2005. Experience of using convalescent plasma for severe acute respiratory syndrome
- 622 among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 56:919–922.
- 623 29. Enria D, Briggiler A, Fernandez N, Levis S, Maiztegui J. 1984. Importance of dose of neutralising
- 624 antibodies in treatment of Agentine Haemorrhagic Fever with immune plasma. The Lancet 255–
- 625 256.

626	30. 🤆	Gudbjartsson DF	, Norddahl GL	, Melsted P	, Gunnarsdottir K	, Holm H,	E١	vthorsson E	, Arnthorsson A
			,			,	_	,	

- 627 Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B, Kristjansdottir S, Birgisdottir K,
- 628 Kristinsdottir AM, Sigurdsson MI, Arnadottir GA, Ivarsdottir EV, Andresdottir M, Jonsson F,
- 629 Agustsdottir AB, Berglund J, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Gottfredsson M,
- 630 Gretarsdottir OS, Gudmundsdottir S, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Helgason A,
- 631 Jensson BO, Jonasdottir A, Jonsson H, Kristjansson T, Kristinsson KG, Magnusdottir DN, Magnusson
- 632 OT, Olafsdottir LB, Rognvaldsson S, le Roux L, Sigmundsdottir G, Sigurdsson A, Sveinbjornsson G,
- 633 Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Thordardottir M,
- 634 Saemundsdottir J, Kristjansson SH, Josefsdottir KS, Masson G, Georgsson G, Kristjansson M, Moller
- A, Palsson R, Gudnason T, Thorsteinsdottir U, Jonsdottir I, Sulem P, Stefansson K. 2020. Humoral
- 636 Immune Response to SARS-CoV-2 in Iceland. N Engl J Med NEJMoa2026116.
- 637 31. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son H-J, Yu S, Park JW, Choo EJ, Park S, Loeb M,
- 638 Kim TH. 2020. Clinical Course and Molecular Viral Shedding Among Asymptomatic and
- 639 Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the
- 640 Republic of Korea. JAMA Intern Med https://doi.org/10.1001/jamainternmed.2020.3862.
- Schober P, Boer C, Schwarte LA. 2018. Correlation Coefficients: Appropriate Use and Interpretation.
 Anesth Analg 126:1763–1768.
- 643 33. Rights JD, Sterba SK. Quantifying explained variance in multilevel models: An integrative framework
 644 for defining R-squared measures. Psychol Methods 24:309–338.
- 645 34. Rights JD, Sterba SK. A framework of R-squared measures for single-level and multilevel regression
 646 mixture models. Psychol Methods 23:434–457.

- 647 35. Rights JD, Sterba SK. New Recommendations on the Use of R-Squared Differences in Multilevel
- 648 Model Comparisons. Multivar Behav Res 55:568–599.
- 649 36. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang
- 50 J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. 2020. A neutralizing
- 651 human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science
- 652 eabc6952.
- 653 37. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF-W, Sahi V, Figueroa A, Guo XV, Cerutti
- 654 G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen K-Y, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y,
- 655 Shapiro L, Ho DD. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2
- 656 spike. Nature 584:450–456.
- 657 38. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Rawson S, Rits-Volloch S, Chen B. 2020.
- 658 Distinct conformational states of SARS-CoV-2 spike protein. Science eabd4251.